Adamas Pharmaceuticals (NASDAQ:ADMS) has published trial data indicating its Gocovri has maintained its treatment effect on motor complications for at least two years.

Phase III – Adamas Pharmaceuticals Inc., of Emeryville, Calif. Reported in the Journal of Parkinson’s Disease final results from 2-year open-label study that demonstrated a sustained improvement in levodopa-induced dyskinesia (LID) among patients using Gocovri (amantadine) extended-release capsules; results demonstrated the treatment effect on motor complications was maintained for at least 2 years; median…

The vice president of Medical Affairs at Adamas Pharmaceuticals discussed the context of these results and what the clinical community should take away from the data from the EASE LID 2 trial of amantadine (Gocovri).

Long-term treatment with Gocovri (amantadine) extended-release capsules was safe and led to sustained reductions in dyskinesia — involuntary, jerky movements — and off episodes in people with Parkinson’s disease, final data from a two-year Phase 3 clinical trial show.

The USPTO has issued a new patent to Adamas Pharmaceuticals (ADMS +1.4%) covering a method [Gocovri (amantadine)] of reducing “OFF” time and increasing “ON” time in Parkinson’s disease patients, the second patent it has received covering the reduction of “OFF” time.

Ranked by Bay Area employees Locally Researched by: Ahalya Srikant, San Francisco Business Times May 22, 2020, 3:00am PDT This List includes biopharmaceutical companies located in the Greater Bay Area, which is defined as Alameda, Contra Costa, Marin, Napa, San Francisco, San Mateo, Santa Clara, Solano and Sonoma counties.

The U.S. Food and Drug Administration (FDA) has agreed to review Adamas Pharmaceutical’s application asking that oral Gocovri (amantadine) also be approved to treat off episodes in Parkinson’s disease patients using levodopa.

Adamas Pharmaceuticals has decided to stop further clinical development of ADS-5102 (amantadine), intended to help people with multiple sclerosis (MS) who have difficulties with walking. The decision came after the company reviewed findings from a comprehensive analysis of its Phase 3 INROADS trial, which assessed the safety and efficacy of ADS-5102 in 594 MS patients

Adamas Pharmaceuticals continues to develop solutions to neurological diseases with proven leadership and experienced vision.